---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-104986"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:58:24.542350+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# IN8bio reports Q2 net loss of $5.1M; 4-year PFS milestone in glioblastoma trial

## Summary
- Net loss $5.1M ($1.24/sh) vs $8.6M ($5.51/sh) in Q2 2024; R&D expenses down to $2.5M from $5.2M.
- Cash $13.2M as of June 30, 2025 (up from $10.2M year ago); runway extended into June 2026.
- INB-200 trial patient surpasses 4 years without progression; mPFS 16.1 months for multi-dose patients (standard of care 6.9 months).
- Preclinical data at ASGCT 2025: INB-619 achieves complete B cell depletion in lupus samples without significant inflammatory cytokines.
- Received Host Region USA East Abstract Award at ISCT 2025 for DeltEx manufacturing platform.

## SEC filing metadata
- accession: 0000950170-25-104986
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000095017025104986/0000950170-25-104986-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000095017025104986/inab-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-104986
- JSON: https://secwatch.observer/filing/0000950170-25-104986.json
- Plain text: https://secwatch.observer/filing/0000950170-25-104986.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.